Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Analysts give Xenon a consensus “Buy” rating (19 analysts: 1 sell, 16 buy, 2 strong buy) with an average 1‑year price target of about $71.88 and several firms assigning targets up to $100.
• Insiders have been selling recently: CEO Ian Mortimer sold 270,000 shares at an average $60.33 (about $16.29M), and insiders sold ~296,707 shares worth $17.85M over the past three months, leaving insiders with 4.07% ownership.
• Xenon is a clinical‑stage biopharma with a $4.86B market cap, the stock trading around $58.40 (52‑week range $28.19–$63.95), and it reported a loss of $1.31 EPS last quarter versus expectations, with analysts forecasting about -3.1 EPS for the year.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has received a consensus recommendation of "Buy" from the nineteen analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $71.8824.

Several research firms recently commented on XENE. Weiss Ratings reissued a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a report on Wednesday. Bank of America reaffirmed a "buy" rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a research report on Monday, March 9th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an "outperform" rating and a $60.00 target price on the stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 270,000 shares of the business's stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the sale, the chief executive officer owned 6,000 shares in the company, valued at approximately $361,980. The trade was a 97.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher John Kenney sold 2,771 shares of the business's stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the sale, the insider owned 4,729 shares of the company's stock, valued at $284,260.19. This represents a 36.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 296,707 shares of company stock worth $17,845,365 over the last three months. Insiders own 4.07% of the company's stock.

Institutional Trading of Xenon Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter worth about $32,000. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 717 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $33,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter worth about $39,000. Finally, Osaic Holdings Inc. increased its position in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 1,034 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Down 0.3%

NASDAQ XENE opened at $58.40 on Friday. Xenon Pharmaceuticals has a 52 week low of $28.19 and a 52 week high of $63.95. The stock has a market capitalization of $4.86 billion, a PE ratio of -13.39 and a beta of 0.74. The firm has a 50 day moving average of $49.58 and a two-hundred day moving average of $44.45.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same quarter last year, the business posted ($0.84) EPS. On average, equities research analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.